Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147831 | 0.81 | MEN1 (0.35) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL17475498 | 0.73 | MEN1 (0.45) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL1684422 | 0.71 | MEN1 (0.55) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL13359174 | 0.70 | MEN1 (0.43) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL17372745 | 0.70 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL1284719 | 0.69 | MEN1 (0.39) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL4214069 | 0.69 | VHL (0.43) | MEN1KMT2ALMNAALDH1A1NPC1 | |
| SCHEMBL67173 | 0.69 | RIPK1 (0.56) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL1362512 | 0.69 | LMNA (0.46) | MEN1KMT2ALMNAALDH1A1HTT | |
| SCHEMBL2518702 | 0.68 | RIPK1 (0.40) | MEN1KMT2ALMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2315756-A2 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2011-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | MEN1 1453/4885KMT2A 1071/4885LMNA 4790/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | MEN1 1453/4885KMT2A 1071/4885LMNA 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.